Biosimilar Remicade Will Pit Rising Cost Pressures Against Prescriber Caution

If approved in Europe this year, as expected, Celltrion/Hospira’s biosimilar infliximab will provide a compelling test of whether and how quickly budgetary pressures can override physician caution. It will also set the stage for the $70 billion worth of copycat antibodies in development.

The forthcoming European approval of Hospira Inc./Celltrion Inc.’s biosimilar infliximab – a copy of rheumatoid arthritis drug Remicade – is an important date on the biosimilars calendar. Assuming, as most do, that the European Medicines Agency (EMA) will give it the nod, the drug – which Celltrion will co-market in the EU 27 as Remsima and Hospira will sell as Inflectra – will be the first biosimilar mAb to reach Europe, or any Western developed market. The first of a wave of complex biosimilars, mostly monoclonal antibodies, it could generate far more exciting returns than seen for first-generation copycat biologics such as erythropoietin (EPO) or filgrastim.

The case in favor of biosimilars looks even more compelling in the midst of the deepest and longest economic recession...

More from Global Vision

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.